APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulomatosis with Polyangiitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Granulomatosis with Polyangiitis Drug Market Analysis and Forecast 2026-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchGranulomatosis with Polyangiitis Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulomatosis with Polyangiitis Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Granulomatosis with Polyangiitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulomatosis with Polyangiitis Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulomatosis with Polyangiitis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulomatosis with Polyangiitis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Granulomatosis with Polyangiitis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Granulomatosis with Polyangiitis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Granulomatosis with Polyangiitis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Granulomatosis with Polyangiitis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Granulomatosis with Polyangiitis Drug include Sandoz International GmbH, GlaxoSmithKline Plc, The International Biotechnology Center (IBC) Generium, Panacea Biotec Ltd, Iltoo Pharma, Genor BioPharma Co Ltd, Coherus BioSciences Inc, ChemoCentryx Inc and Bristol-Myers Squibb Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Granulomatosis with Polyangiitis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Granulomatosis with Polyangiitis Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Granulomatosis with Polyangiitis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Granulomatosis with Polyangiitis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Granulomatosis with Polyangiitis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Granulomatosis with Polyangiitis Drug sales, projected growth trends, production technology, application and end-user industry.

Granulomatosis with Polyangiitis Drug Segment by Company

Sandoz International GmbH

GlaxoSmithKline Plc

The International Biotechnology Center (IBC) Generium

Panacea Biotec Ltd

Iltoo Pharma

Genor BioPharma Co Ltd

Coherus BioSciences Inc

ChemoCentryx Inc

Bristol-Myers Squibb Company

Bionovis SA

Granulomatosis with Polyangiitis Drug Segment by Type

Avacopan

Benralizumab

Rituximab Biosimilar

Others

Granulomatosis with Polyangiitis Drug Segment by Application

Hospital

Clinic

Others

Granulomatosis with Polyangiitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulomatosis with Polyangiitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulomatosis with Polyangiitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulomatosis with Polyangiitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Granulomatosis with Polyangiitis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Granulomatosis with Polyangiitis Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Avacopan Major Manufacturers Table 3. Benralizumab Major Manufacturers Table 4. Rituximab Biosimilar Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Granulomatosis with Polyangiitis Drug Industry Trends Table 11. Granulomatosis with Polyangiitis Drug Industry Drivers Table 12. Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges Table 13. Granulomatosis with Polyangiitis Drug Industry Restraints Table 14. Global Granulomatosis with Polyangiitis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2021-2026) Table 18. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2027-2032) Table 19. Global Granulomatosis with Polyangiitis Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 20. Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026) & (W Units) Table 21. Global Granulomatosis with Polyangiitis Drug Sales by Region (2027-2032) & (W Units) Table 22. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2021-2026) Table 23. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2027-2032) Table 24. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global Granulomatosis with Polyangiitis Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Granulomatosis with Polyangiitis Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Granulomatosis with Polyangiitis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Granulomatosis with Polyangiitis Drug Manufacturers, Product Type & Application Table 32. Global Granulomatosis with Polyangiitis Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Granulomatosis with Polyangiitis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Granulomatosis with Polyangiitis Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2026) Table 39. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2027-2032) Table 40. Global Granulomatosis with Polyangiitis Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 41. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 42. Global Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 43. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2026) Table 44. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2027-2032) Table 45. Global Granulomatosis with Polyangiitis Drug Price by Type (2021-2026) & (US$/Unit) Table 46. Global Granulomatosis with Polyangiitis Drug Price by Type (2027-2032) & (US$/Unit) Table 47. Global Granulomatosis with Polyangiitis Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2026) Table 51. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2027-2032) Table 52. Global Granulomatosis with Polyangiitis Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 53. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 54. Global Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 55. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2026) Table 56. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2027-2032) Table 57. Global Granulomatosis with Polyangiitis Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Granulomatosis with Polyangiitis Drug Price by Application (2027-2032) & (US$/Unit) Table 59. Sandoz International GmbH Company Information Table 60. Sandoz International GmbH Business Overview Table 61. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio Table 63. Sandoz International GmbH Recent Development Table 64. GlaxoSmithKline Plc Company Information Table 65. GlaxoSmithKline Plc Business Overview Table 66. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio Table 68. GlaxoSmithKline Plc Recent Development Table 69. The International Biotechnology Center (IBC) Generium Company Information Table 70. The International Biotechnology Center (IBC) Generium Business Overview Table 71. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio Table 73. The International Biotechnology Center (IBC) Generium Recent Development Table 74. Panacea Biotec Ltd Company Information Table 75. Panacea Biotec Ltd Business Overview Table 76. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 78. Panacea Biotec Ltd Recent Development Table 79. Iltoo Pharma Company Information Table 80. Iltoo Pharma Business Overview Table 81. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio Table 83. Iltoo Pharma Recent Development Table 84. Genor BioPharma Co Ltd Company Information Table 85. Genor BioPharma Co Ltd Business Overview Table 86. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 88. Genor BioPharma Co Ltd Recent Development Table 89. Coherus BioSciences Inc Company Information Table 90. Coherus BioSciences Inc Business Overview Table 91. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 93. Coherus BioSciences Inc Recent Development Table 94. ChemoCentryx Inc Company Information Table 95. ChemoCentryx Inc Business Overview Table 96. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 98. ChemoCentryx Inc Recent Development Table 99. Bristol-Myers Squibb Company Company Information Table 100. Bristol-Myers Squibb Company Business Overview Table 101. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio Table 103. Bristol-Myers Squibb Company Recent Development Table 104. Bionovis SA Company Information Table 105. Bionovis SA Business Overview Table 106. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio Table 108. Bionovis SA Recent Development Table 109. North America Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 112. North America Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 113. North America Granulomatosis with Polyangiitis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 114. North America Granulomatosis with Polyangiitis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 115. North America Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 118. North America Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 119. North America Granulomatosis with Polyangiitis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 120. North America Granulomatosis with Polyangiitis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 121. North America Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 123. North America Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 124. North America Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 125. North America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 126. North America Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 127. North America Granulomatosis with Polyangiitis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 128. North America Granulomatosis with Polyangiitis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 129. United States Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 130. Canada Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 131. Mexico Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 132. Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 133. Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 134. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 135. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 136. Europe Granulomatosis with Polyangiitis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 137. Europe Granulomatosis with Polyangiitis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 138. Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 139. Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 140. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 141. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 142. Europe Granulomatosis with Polyangiitis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 143. Europe Granulomatosis with Polyangiitis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 144. Europe Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Europe Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 146. Europe Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 147. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 148. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 149. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 150. Europe Granulomatosis with Polyangiitis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 151. Europe Granulomatosis with Polyangiitis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 152. Germany Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 153. France Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 154. U.K. Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 155. Italy Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 156. Russia Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 157. Spain Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 158. Netherlands Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 159. Switzerland Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 160. Sweden Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 161. Poland Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 162. China Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 163. China Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 164. China Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 165. China Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 166. China Granulomatosis with Polyangiitis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 167. China Granulomatosis with Polyangiitis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 168. China Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 169. China Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 170. China Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 171. China Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 172. China Granulomatosis with Polyangiitis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 173. China Granulomatosis with Polyangiitis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 174. Asia Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 175. Asia Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 176. Asia Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 177. Asia Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 178. Asia Granulomatosis with Polyangiitis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 179. Asia Granulomatosis with Polyangiitis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 180. Asia Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 181. Asia Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 182. Asia Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 183. Asia Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 184. Asia Granulomatosis with Polyangiitis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 185. Asia Granulomatosis with Polyangiitis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 186. Asia Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 187. Asia Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 188. Asia Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 189. Asia Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 190. Asia Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 191. Asia Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 192. Asia Granulomatosis with Polyangiitis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 193. Asia Granulomatosis with Polyangiitis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 194. Japan Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 195. South Korea Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 196. India Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 197. Australia Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 198. Taiwan Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 199. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 200. SAMEA Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (US$ Million) Table 201. SAMEA Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (US$ Million) Table 202. SAMEA Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 203. SAMEA Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 204. SAMEA Granulomatosis with Polyangiitis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 205. SAMEA Granulomatosis with Polyangiitis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 206. SAMEA Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (US$ Million) Table 207. SAMEA Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (US$ Million) Table 208. SAMEA Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 209. SAMEA Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 210. SAMEA Granulomatosis with Polyangiitis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 211. SAMEA Granulomatosis with Polyangiitis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 212. SAMEA Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 213. SAMEA Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 214. SAMEA Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 215. SAMEA Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 216. SAMEA Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 217. SAMEA Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 218. SAMEA Granulomatosis with Polyangiitis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 219. SAMEA Granulomatosis with Polyangiitis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 220. Brazil Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 221. Argentina Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 222. Chile Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 223. Colombia Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 224. Peru Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 225. Saudi Arabia Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 226. Israel Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 227. UAE Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 228. Turkey Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 229. Iran Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 230. Egypt Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Table 231. Key Raw Materials Table 232. Raw Materials Key Suppliers Table 233. Granulomatosis with Polyangiitis Drug Distributors List Table 234. Granulomatosis with Polyangiitis Drug Customers List Table 235. Research Programs/Design for This Report Table 236. Authors List of This Report Table 237. Secondary Sources Table 238. Primary Sources List of Figures Figure 1. Granulomatosis with Polyangiitis Drug Image Figure 2. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulomatosis with Polyangiitis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Avacopan Image Figure 5. Benralizumab Image Figure 6. Rituximab Biosimilar Image Figure 7. Others Image Figure 8. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Granulomatosis with Polyangiitis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global Granulomatosis with Polyangiitis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2021-2032) Figure 18. Global Granulomatosis with Polyangiitis Drug Sales (2021-2032) & (W Units) Figure 19. Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 20. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Granulomatosis with Polyangiitis Drug Sales YoY (2021-2032) & (W Units) Figure 22. Europe Granulomatosis with Polyangiitis Drug Sales YoY (2021-2032) & (W Units) Figure 23. China Granulomatosis with Polyangiitis Drug Sales YoY (2021-2032) & (W Units) Figure 24. Asia (Excluding China) Granulomatosis with Polyangiitis Drug Sales YoY (2021-2032) & (W Units) Figure 25. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales YoY (2021-2032) & (W Units) Figure 26. Global Granulomatosis with Polyangiitis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Granulomatosis with Polyangiitis Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2032) Figure 32. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 33. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2032) Figure 35. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2032) Figure 38. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 39. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2032) Figure 41. North America Granulomatosis with Polyangiitis Drug Revenue Share by Type (2021-2032) Figure 42. North America Granulomatosis with Polyangiitis Drug Sales Share by Type (2021-2032) Figure 43. North America Granulomatosis with Polyangiitis Drug Revenue Share by Application (2021-2032) Figure 44. North America Granulomatosis with Polyangiitis Drug Sales Share by Application (2021-2032) Figure 45. North America Granulomatosis with Polyangiitis Drug Revenue Share by Country (2021-2032) Figure 46. North America Granulomatosis with Polyangiitis Drug Sales Share by Country (2021-2032) Figure 47. Europe Granulomatosis with Polyangiitis Drug Revenue Share by Type (2021-2032) Figure 48. Europe Granulomatosis with Polyangiitis Drug Sales Share by Type (2021-2032) Figure 49. Europe Granulomatosis with Polyangiitis Drug Revenue Share by Application (2021-2032) Figure 50. Europe Granulomatosis with Polyangiitis Drug Sales Share by Application (2021-2032) Figure 51. Europe Granulomatosis with Polyangiitis Drug Revenue Share by Country (2021-2032) Figure 52. Europe Granulomatosis with Polyangiitis Drug Sales Share by Country (2021-2032) Figure 53. China Granulomatosis with Polyangiitis Drug Revenue Share by Type (2021-2032) Figure 54. China Granulomatosis with Polyangiitis Drug Sales Share by Type (2021-2032) Figure 55. China Granulomatosis with Polyangiitis Drug Revenue Share by Application (2021-2032) Figure 56. China Granulomatosis with Polyangiitis Drug Sales Share by Application (2021-2032) Figure 57. Asia Granulomatosis with Polyangiitis Drug Revenue Share by Type (2021-2032) Figure 58. Asia Granulomatosis with Polyangiitis Drug Sales Share by Type (2021-2032) Figure 59. Asia Granulomatosis with Polyangiitis Drug Revenue Share by Application (2021-2032) Figure 60. Asia Granulomatosis with Polyangiitis Drug Sales Share by Application (2021-2032) Figure 61. Asia Granulomatosis with Polyangiitis Drug Revenue Share by Country (2021-2032) Figure 62. Asia Granulomatosis with Polyangiitis Drug Sales Share by Country (2021-2032) Figure 63. SAMEA Granulomatosis with Polyangiitis Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA Granulomatosis with Polyangiitis Drug Sales Share by Type (2021-2032) Figure 65. SAMEA Granulomatosis with Polyangiitis Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA Granulomatosis with Polyangiitis Drug Sales Share by Application (2021-2032) Figure 67. SAMEA Granulomatosis with Polyangiitis Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA Granulomatosis with Polyangiitis Drug Sales Share by Country (2021-2032) Figure 69. Granulomatosis with Polyangiitis Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Granulomatosis with Polyangiitis Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Avacopan
  • Benralizumab
  • Rituximab Biosimilar
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • GlaxoSmithKline Plc
  • The International Biotechnology Center (IBC) Generium
  • Panacea Biotec Ltd
  • Iltoo Pharma
  • Genor BioPharma Co Ltd
  • Coherus BioSciences Inc
  • ChemoCentryx Inc
  • Bristol-Myers Squibb Company
  • Bionovis SA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Granulomatosis with Polyangiitis Drug Market by Type
  3. 1.2.1 Global Granulomatosis with Polyangiitis Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Avacopan
  5. 1.2.3 Benralizumab
  6. 1.2.4 Rituximab Biosimilar
  7. 1.2.5 Others
  8. 1.3 Granulomatosis with Polyangiitis Drug Market by Application
  9. 1.3.1 Global Granulomatosis with Polyangiitis Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Granulomatosis with Polyangiitis Drug Market Dynamics
  1. 2.1 Granulomatosis with Polyangiitis Drug Industry Trends
  2. 2.2 Granulomatosis with Polyangiitis Drug Industry Drivers
  3. 2.3 Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges
  4. 2.4 Granulomatosis with Polyangiitis Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Granulomatosis with Polyangiitis Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region
  3. 3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Granulomatosis with Polyangiitis Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Granulomatosis with Polyangiitis Drug Sales by Region
  9. 3.4.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Granulomatosis with Polyangiitis Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers
  2. 4.1.1 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Granulomatosis with Polyangiitis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers
  6. 4.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Granulomatosis with Polyangiitis Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Granulomatosis with Polyangiitis Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Granulomatosis with Polyangiitis Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Granulomatosis with Polyangiitis Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Granulomatosis with Polyangiitis Drug Manufacturers, Product Type & Application
  13. 4.7 Global Granulomatosis with Polyangiitis Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Granulomatosis with Polyangiitis Drug Market CR5 and HHI
  16. 4.8.2 2025 Granulomatosis with Polyangiitis Drug Tier 1, Tier 2, and Tier 3
5 Granulomatosis with Polyangiitis Drug Market by Type
  1. 5.1 Global Granulomatosis with Polyangiitis Drug Revenue by Type
  2. 5.1.1 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Granulomatosis with Polyangiitis Drug Sales by Type
  6. 5.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Granulomatosis with Polyangiitis Drug Price by Type
6 Granulomatosis with Polyangiitis Drug Market by Application
  1. 6.1 Global Granulomatosis with Polyangiitis Drug Revenue by Application
  2. 6.1.1 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Granulomatosis with Polyangiitis Drug Sales by Application
  6. 6.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Granulomatosis with Polyangiitis Drug Price by Application
7 Company Profiles
  1. 7.1 Sandoz International GmbH
  2. 7.1.1 Sandoz International GmbH Company Information
  3. 7.1.2 Sandoz International GmbH Business Overview
  4. 7.1.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
  6. 7.1.5 Sandoz International GmbH Recent Developments
  7. 7.2 GlaxoSmithKline Plc
  8. 7.2.1 GlaxoSmithKline Plc Company Information
  9. 7.2.2 GlaxoSmithKline Plc Business Overview
  10. 7.2.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
  12. 7.2.5 GlaxoSmithKline Plc Recent Developments
  13. 7.3 The International Biotechnology Center (IBC) Generium
  14. 7.3.1 The International Biotechnology Center (IBC) Generium Company Information
  15. 7.3.2 The International Biotechnology Center (IBC) Generium Business Overview
  16. 7.3.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
  18. 7.3.5 The International Biotechnology Center (IBC) Generium Recent Developments
  19. 7.4 Panacea Biotec Ltd
  20. 7.4.1 Panacea Biotec Ltd Company Information
  21. 7.4.2 Panacea Biotec Ltd Business Overview
  22. 7.4.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  24. 7.4.5 Panacea Biotec Ltd Recent Developments
  25. 7.5 Iltoo Pharma
  26. 7.5.1 Iltoo Pharma Company Information
  27. 7.5.2 Iltoo Pharma Business Overview
  28. 7.5.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
  30. 7.5.5 Iltoo Pharma Recent Developments
  31. 7.6 Genor BioPharma Co Ltd
  32. 7.6.1 Genor BioPharma Co Ltd Company Information
  33. 7.6.2 Genor BioPharma Co Ltd Business Overview
  34. 7.6.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  36. 7.6.5 Genor BioPharma Co Ltd Recent Developments
  37. 7.7 Coherus BioSciences Inc
  38. 7.7.1 Coherus BioSciences Inc Company Information
  39. 7.7.2 Coherus BioSciences Inc Business Overview
  40. 7.7.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  42. 7.7.5 Coherus BioSciences Inc Recent Developments
  43. 7.8 ChemoCentryx Inc
  44. 7.8.1 ChemoCentryx Inc Company Information
  45. 7.8.2 ChemoCentryx Inc Business Overview
  46. 7.8.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  48. 7.8.5 ChemoCentryx Inc Recent Developments
  49. 7.9 Bristol-Myers Squibb Company
  50. 7.9.1 Bristol-Myers Squibb Company Company Information
  51. 7.9.2 Bristol-Myers Squibb Company Business Overview
  52. 7.9.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
  54. 7.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 7.10 Bionovis SA
  56. 7.10.1 Bionovis SA Company Information
  57. 7.10.2 Bionovis SA Business Overview
  58. 7.10.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
  60. 7.10.5 Bionovis SA Recent Developments
8 North America
  1. 8.1 North America Granulomatosis with Polyangiitis Drug Market Size by Type
  2. 8.1.1 North America Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Granulomatosis with Polyangiitis Drug Price by Type (2021-2032)
  5. 8.2 North America Granulomatosis with Polyangiitis Drug Market Size by Application
  6. 8.2.1 North America Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Granulomatosis with Polyangiitis Drug Price by Application (2021-2032)
  9. 8.3 North America Granulomatosis with Polyangiitis Drug Market Size by Country
  10. 8.3.1 North America Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Granulomatosis with Polyangiitis Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Granulomatosis with Polyangiitis Drug Market Size by Type
  2. 9.1.1 Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Granulomatosis with Polyangiitis Drug Price by Type (2021-2032)
  5. 9.2 Europe Granulomatosis with Polyangiitis Drug Market Size by Application
  6. 9.2.1 Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Granulomatosis with Polyangiitis Drug Price by Application (2021-2032)
  9. 9.3 Europe Granulomatosis with Polyangiitis Drug Market Size by Country
  10. 9.3.1 Europe Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Granulomatosis with Polyangiitis Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Granulomatosis with Polyangiitis Drug Market Size by Type
  2. 10.1.1 China Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
  4. 10.1.3 China Granulomatosis with Polyangiitis Drug Price by Type (2021-2032)
  5. 10.2 China Granulomatosis with Polyangiitis Drug Market Size by Application
  6. 10.2.1 China Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
  8. 10.2.3 China Granulomatosis with Polyangiitis Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Granulomatosis with Polyangiitis Drug Market Size by Type
  2. 11.1.1 Asia Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Granulomatosis with Polyangiitis Drug Price by Type (2021-2032)
  5. 11.2 Asia Granulomatosis with Polyangiitis Drug Market Size by Application
  6. 11.2.1 Asia Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Granulomatosis with Polyangiitis Drug Price by Application (2021-2032)
  9. 11.3 Asia Granulomatosis with Polyangiitis Drug Market Size by Country
  10. 11.3.1 Asia Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Granulomatosis with Polyangiitis Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Granulomatosis with Polyangiitis Drug Market Size by Type
  2. 12.1.1 SAMEA Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Granulomatosis with Polyangiitis Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Granulomatosis with Polyangiitis Drug Market Size by Application
  6. 12.2.1 SAMEA Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Granulomatosis with Polyangiitis Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Granulomatosis with Polyangiitis Drug Market Size by Country
  10. 12.3.1 SAMEA Granulomatosis with Polyangiitis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Granulomatosis with Polyangiitis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Granulomatosis with Polyangiitis Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Granulomatosis with Polyangiitis Drug Value Chain Analysis
  2. 13.1.1 Granulomatosis with Polyangiitis Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Granulomatosis with Polyangiitis Drug Production Mode & Process
  6. 13.2 Granulomatosis with Polyangiitis Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Granulomatosis with Polyangiitis Drug Distributors
  9. 13.2.3 Granulomatosis with Polyangiitis Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst